Downregulation of WIF-1 by hypermethylation in astrocytomas

Zhuanyi Yang1, Ying Wang, Jiasheng Fang

  • 1Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China.

Insights

Wnt inhibitory factor-1 (WIF-1) gene silencing by promoter methylation is frequent in astrocytomas, leading to Wnt pathway activation and tumor development. This epigenetic silencing contributes to astrocytoma progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Wnt inhibitory factor-1 (WIF-1) is a Wnt antagonist and tumor suppressor.
  • Aberrant Wnt signaling, driven by WIF-1 promoter hypermethylation and low expression, contributes to human tumor development.
  • Understanding WIF-1's role in astrocytoma is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the expression and methylation status of the WIF-1 gene in astrocytoma.
  • To determine the association between WIF-1 alterations and astrocytoma pathological grade.
  • To explore the potential of WIF-1 re-expression via demethylation in glioblastoma cell lines.

Main Methods:

  • RT-PCR and immunohistochemistry were used to assess WIF-1 mRNA and protein expression.
  • Methylation-specific PCR analyzed WIF-1 gene promoter methylation.
  • Glioblastoma cell lines were treated with a demethylating agent (5-aza-2'-deoxycytidine).

Main Results:

  • Significant downregulation of WIF-1 mRNA and protein was observed in astrocytoma tissues compared to normal brain tissues.
  • WIF-1 downregulation correlated significantly with higher astrocytoma pathological grades.
  • Aberrant WIF-1 promoter methylation was detected in 54.29% of astrocytoma samples, correlating with reduced WIF-1 expression.
  • Demethylating agent treatment restored WIF-1 expression in glioblastoma cell lines with silenced WIF-1.

Conclusions:

  • The WIF-1 gene is frequently silenced in astrocytomas through aberrant promoter methylation.
  • Epigenetic silencing of WIF-1 is a potential mechanism driving astrocytoma carcinogenesis.
  • Targeting WIF-1 methylation could offer a therapeutic strategy for astrocytoma.